Browse > Article
http://dx.doi.org/10.4046/trd.2017.0096

Factors Associated with Persistent Sputum Positivity at the End of the Second Month of Tuberculosis Treatment in Lithuania  

Diktanas, Saulius (Vilnius University Hospital Santariskiu Klinikos, Center of Pulmonology and Allergology)
Vasiliauskiene, Edita (Vilnius University Hospital Santariskiu Klinikos, Center of Laboratory Medicine)
Polubenko, Katazyna (Vilnius University, Faculty of Medicine)
Danila, Edvardas (Vilnius University Hospital Santariskiu Klinikos, Center of Pulmonology and Allergology)
Celedinaite, Indre (Vilnius University, Faculty of Medicine)
Boreikaite, Evelina (Vilnius University, Faculty of Medicine)
Misiunas, Kipras (Vilnius University, Faculty of Medicine)
Publication Information
Tuberculosis and Respiratory Diseases / v.81, no.3, 2018 , pp. 233-240 More about this Journal
Abstract
Background: Non-conversion of sputum smear and culture prolongs the infectivity of the patient and has been associated with unfavorable outcomes. We aimed to evaluate factors associated with persistent sputum positivity at the end of two months of treatment of new case pulmonary tuberculosis (TB). Methods: Data of 87 human immunodeficiency virus-negative patients with culture-positive drug-susceptible pulmonary TB admitted to local university hospital between September 2015 and September 2016 were reviewed. Factors associated with sputum smear and/or culture positivity at the end of the second month of treatment were analyzed. Results: Twenty-two patients (25.3%) remained smear and/or culture-positive. Male sex, lower body mass index (BMI), unemployment, alcohol abuse, higher number of lobes involved and cavities on chest X-rays, shorter time to detection (TTD) on liquid cultures, higher respiratory sample smear grading and colony count in solid cultures, higher C-reactive protein, erythrocyte sedimentation rate, leukocytosis, thrombocytosis, and anemia were all significantly associated with persistent sputum positivity. However, in the logistic regression analysis only male sex, lower BMI, alcohol abuse, higher radiological involvement, cavitation, higher smear grading, higher colony count in solid cultures and shorter TTD were determined as independent factors associated with persistent sputum positivity at the end of 2 months of treatment. Conclusion: In conclusion, higher sputum smear and culture grading at diagnosis, shorter TTD, higher number of lobes involved, cavitation, male sex, alcohol abuse, and lower BMI were independently associated with persistent sputum positivity. These factors should be sought when distinguishing which patients will remain infectious longer and possibly have worse outcomes.
Keywords
Tuberculosis; Risk Factors; Treatment Outcome; Sputum;
Citations & Related Records
연도 인용수 순위
  • Reference
1 International Union Against Tuberculosis and Lung Disease. International Union Against Tuberculosis and Lung Disease recommended grading of smear microscopy. Paris: International Union Against Tuberculosis and Lung Disease; 2000.
2 Hesseling AC, Walzl G, Enarson DA, Carroll NM, Duncan K, Lukey PT, et al. Baseline sputum time to detection predicts month two culture conversion and relapse in non-HIV-infected patients. Int J Tuberc Lung Dis 2010;14:560-70.
3 Su WJ, Feng JY, Chiu YC, Huang SF, Lee YC. Role of 2-month sputum smears in predicting culture conversion in pulmonary tuberculosis. Eur Respir J 2011;37:376-83.   DOI
4 Pheiffer C, Carroll NM, Beyers N, Donald P, Duncan K, Uys P, et al. Time to detection of Mycobacterium tuberculosis in BACTEC systems as a viable alternative to colony counting. Int J Tuberc Lung Dis 2008;12:792-8.
5 Pajankar S, Khandekar R, Al Amri MA, Al Lawati MR. Factors influencing sputum smear conversion at one and two months of tuberculosis treatment. Oman Med J 2008;23:263-8.
6 Chao WC, Huang YW, Yu MC, Yang WT, Lin CJ, Lee JJ, et al. Outcome correlation of smear-positivity but culture-negativity during standard anti-tuberculosis treatment in Taiwan. BMC Infect Dis 2015;15:67.   DOI
7 Dorman SE, Johnson JL, Goldberg S, Muzanye G, Padayatchi N, Bozeman L, et al. Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med 2009;180:273-80.   DOI
8 Northcote J, Livingston M. Accuracy of self-reported drinking: observational verification of ‘last occasion’ drink estimates of young adults. Alcohol Alcohol 2011;46:709-13.   DOI
9 Romeo J, Warnberg J, Nova E, Diaz LE, Gomez-Martinez S, Marcos A. Moderate alcohol consumption and the immune system: a review. Br J Nutr 2007;98 Suppl 1:S111-5.
10 Kliiman K, Altraja A. Predictors and mortality associated with treatment default in pulmonary tuberculosis. Int J Tuberc Lung Dis 2010;14:454-63.
11 Jakubowiak WM, Bogorodskaya EM, Borisov SE, Danilova ID, Kourbatova EV. Risk factors associated with default among new pulmonary TB patients and social support in six Russian regions. Int J Tuberc Lung Dis 2007;11:46-53.
12 Waitt CJ, Squire SB. A systematic review of risk factors for death in adults during and after tuberculosis treatment. Int J Tuberc Lung Dis 2011;15:871-85.   DOI
13 Bouti K, Aharmim M, Marc K, Soualhi M, Zahraoui R, Bena- mor J, et al. Factors influencing sputum conversion among smear-positive pulmonary tuberculosis patients in Morocco. ISRN Pulmonol 2013;2013:486507.
14 Wang JY, Lee LN, Yu CJ, Chien YJ, Yang PC; TAMI Group. Factors influencing time to smear conversion in patients with smear-positive pulmonary tuberculosis. Respirology 2009;14:1012-9.   DOI
15 National Institute for Health and Care Excellence. Tuberculosis: NICE guideline NG33. London: National Institute for Health and Care Excellence; 2016.
16 Djouma FN, Noubom M, Ateudjieu J, Donfack H. Delay in sputum smear conversion and outcomes of smear-positive tuberculosis patients: a retrospective cohort study in Bafoussam, Cameroon. BMC Infect Dis 2015;15:139.   DOI
17 World Health Organization. Global tuberculosis report 2016. WHO/HTM/TB/2016.23 [Internet]. Geneva: World Health Organization; 2016 [cited 2017 Aug 17]. Available from: http://www.who.int/tb/publications/global_report/en.
18 Epstein MD, Schluger NW, Davidow AL, Bonk S, Rom WN, Hanna B. Time to detection of Mycobacterium tuberculosis in sputum culture correlates with outcome in patients receiving treatment for pulmonary tuberculosis. Chest 1998;113:379- 86.   DOI
19 Vidal R, Martin-Casabona N, Juan A, Falgueras T, Miravitlles M. Incidence and significance of acid-fast bacilli in spu- tum smears at the end of antituberculous treatment. Chest 1996;109:1562-5.   DOI
20 Dominguez-Castellano A, Muniain MA, Rodriguez-Bano J, Garcia M, Rios MJ, Galvez J, et al. Factors associated with time to sputum smear conversion in active pulmonary tuberculosis. Int J Tuberc Lung Dis 2003;7:432-8.
21 Guler M, Unsal E, Dursun B, Aydln O, Capan N. Factors influ- encing sputum smear and culture conversion time among patients with new case pulmonary tuberculosis. Int J Clin Pract 2007;61:231-5.
22 Singla R, Osman MM, Khan N, Al-Sharif N, Al-Sayegh MO, Shaikh MA. Factors predicting persistent sputum smear positivity among pulmonary tuberculosis patients 2 months after treatment. Int J Tuberc Lung Dis 2003;7:58-64.
23 Visser ME, Stead MC, Walzl G, Warren R, Schomaker M, Grewal HM, et al. Baseline predictors of sputum culture conversion in pulmonary tuberculosis: importance of cavities, smoking, time to detection and W-Beijing genotype. PLoS One 2012;7:e29588.   DOI
24 Zierski M, Bek E, Long MW, Snider DE Jr. Short-course (6 month) cooperative tuberculosis study in Poland: results 18 months after completion of treatment. Am Rev Respir Dis 1980;122:879-89.
25 Nagu TJ, Spiegelman D, Hertzmark E, Aboud S, Makani J, Matee MI, et al. Anemia at the initiation of tuberculosis therapy is associated with delayed sputum conversion among pulmo- nary tuberculosis patients in Dar-es-Salaam, Tanzania. PLoS One 2014;9:e91229.   DOI
26 World Health Organization. Definitions and reporting framework for tuberculosis, 2013 revision. WHO/HTM/TB/2013.2. Geneva: World Health Organization; 2014.
27 World Health Organization. WHO global status report on al- cohol and health. Geneva: World Health Organization; 2014.
28 World Health Organization. Guidelines for treatment of tuberculosis. WHO/HTM/TB/2009.420. Geneva: World Health Organization; 2010.
29 European Centre for Disease Prevention and Control; WHO Regional Office for Europe. Tuberculosis surveillance and monitoring in Europe, 2017. Stockholm: European Centre for Disease Prevention and Control; 2017.